F31.3 F31.4 F32.1 F33.1 F33.2
Conditions
Interventions
Group 1: 200 mg of amantadine or placebo as add-on treatment. Cross-over after six weeks.
Group 2: 200 mg of amantadine or placebo as add-on treatment. Cross-over after six weeks.
Sponsors
Medizinische Hochschule Hannover
Eligibility
Sex/Gender
All
Age
30 Years to 70 Years
Inclusion criteria
Inclusion criteria: Acutely depressed patients requiring treatment, according to the ICD-10 classification: F31.3, 31.4, 31.5 as well as F33.0, F33.1, F33.2, F33.3 and the respective DSM-IV criteria Men and women between 30 and 70 years of age Informed consent of the patient
Exclusion criteria
Exclusion criteria: Suspected exogenous depression Hypersensitivity against ingredients of amantadine or the placebo Conditions in which the use of amantadine is contraindicated (e.g. clinically relevant renal insufficiency) Other severe systemic conditions (e.g. cardiovascular conditions, blood coagulation disorders, malignancies requiring palliative care, collagenoses or florid infections) Current pregnancy or breastfeeding Compulsory in-patient treatment Unability to give informed consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change of HAMD rating results after 6 weeks of treatment and BDV activity comparing amantadin and placebo group | — |
Secondary
| Measure | Time frame |
|---|---|
| Beck Depression Inventory (BDI) von Zerssen's Mental State Scale (Bf-S) Symptom Checklist (SCL) Global Assessment Scale (GAS) Cognitive Functions | — |
Countries
Germany
Contacts
Public ContactDetlef Dietrich
Medizinische Hochschule Hannover
Outcome results
None listed